Everest files NDA in Hong Kong for metastatic breast cancer therapy

Everest has submitted a new drug application (NDA) in Hong Kong for sacituzumab govitecan (SG) to treat metastatic triple-negative breast cancer (mTNBC).

Related Keywords

China ,Yang Shi ,Hunan ,Hong Kong Special Administrative Region ,Hong Kong General ,Hong Kong ,Taiwan ,South Korea ,Singapore , ,Department Of Health ,Hong Kong Special Administrative ,Medicines Oncology ,Greater China ,